secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-212069
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Therapeutic Q1 net loss $25.2M; TX45 APEX Phase 2 enrollment near complete
--------------------------------------------------------------------------------

- Net loss $25.2M in Q1 2026 vs. $15.9M in Q1 2025; R&D expense $20.9M (up $7.9M YoY).
- Cash $236.9M as of Mar 31, 2026, providing runway into Q4 2028.
- TX45 APEX Phase 2 in PH-HFpEF enrollment nearing completion; topline data expected late Q4 2026/early Q1 2027.
- TX2100 Phase 1a in HHT ongoing; topline results expected by end of Q3 2026.
- Appointed François Nader as Board Chair and Jessica Chutter as independent director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526212069/0001193125-26-212069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526212069/tecx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-212069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer